» Articles » PMID: 33959026

Injection-Based Management of Osteoarthritis of the Knee: A Systematic Review of Guidelines

Overview
Journal Front Pharmacol
Date 2021 May 7
PMID 33959026
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA) is a leading cause of disability among older adults. Numerous pharmaceutical and nonpharmaceutical interventions have been described. Intra-articular injections are commonly the first line treatment. There are several articles, reporting the outcome of corticosteroids (CS), hyaluronic acid (HA) and platelet rich plasma (PRP). The aim of the study is to highlight the usefulness, indication and efficacy of the intra-articular injection of principal drugs. CSs have been shown to reduce the severity of pain, but care should be taken with repeated injections because of potential harm. HA reported good outcomes both for pain reduction and functional improvement. Different national societies guidelines do not recommend the PRP intra-articular injection in the management of knee OA for lack of evidence. In conclusion, the authors affirm that there is some evidence that intra-articular steroids are efficacious, but their benefit may be relatively short lived (<4 weeks). Most of the positive outcome were limited to the studies or part of the studies that considered the injection of high molecular weight as visco-supplementation, with a course of two to four injections a year.

Citing Articles

Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review.

Glinkowski W, Tomaszewski W J Clin Med. 2025; 14(4).

PMID: 40004802 PMC: 11856182. DOI: 10.3390/jcm14041272.


EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics.

Conrozier T, Raman R, Diracoglu D, Montfort J, Bard H, Baron D Cartilage. 2024; :19476035241271970.

PMID: 39564753 PMC: 11577334. DOI: 10.1177/19476035241271970.


Comparison of functional performance outcomes between oral patented crystalline glucosamine sulfate and platelet-rich plasma among knee osteoarthritis patients: a propensity score matching analysis.

Amarase C, Tanavalee A, Ngarmukos S, Tanavalee C, Jaruthien N, Somrak P Aging Clin Exp Res. 2024; 36(1):168.

PMID: 39126538 PMC: 11316698. DOI: 10.1007/s40520-024-02814-7.


Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts.

Coppola C, Greco M, Munir A, Musaro D, Quarta S, Massaro M Curr Issues Mol Biol. 2024; 46(5):4063-4105.

PMID: 38785519 PMC: 11119992. DOI: 10.3390/cimb46050251.


Wharton's jelly and osteoarthritis of the knee.

Aratikatla A, Maffulli N, Gupta M, Potti I, Potty A, Gupta A Br Med Bull. 2023; 149(1):13-31.

PMID: 38061765 PMC: 10993459. DOI: 10.1093/bmb/ldad030.


References
1.
Lee P, Kim Y, Lim Y, Lee C, Sim W, Ha C . Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial. J Int Med Res. 2006; 34(1):77-87. DOI: 10.1177/147323000603400110. View

2.
McCrum C . Therapeutic Review of Methylprednisolone Acetate Intra-Articular Injection in the Management of Osteoarthritis of the Knee - Part 2: Clinical and Procedural Considerations. Musculoskeletal Care. 2016; 14(4):252-266. DOI: 10.1002/msc.1145. View

3.
Day R, Brooks P, Conaghan P, Petersen M . A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol. 2004; 31(4):775-82. View

4.
Raman R, Dutta A, Day N, Sharma H, Shaw C, JOHNSON G . Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee -- a prospective randomized clinical trial. Knee. 2008; 15(4):318-24. DOI: 10.1016/j.knee.2008.02.012. View

5.
Gaffney K, Ledingham J, Perry J . Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis. 1995; 54(5):379-81. PMC: 1005598. DOI: 10.1136/ard.54.5.379. View